Keep eyes on
$Travere Therapeutic(TVTX.US$ Travere Plans To Submit SNDA To FDA In Q1 2024 For Conversion Of Existing US Accelerated Approval Of FILSPARI (Sparsentan) In IgAN To Full Approval![]()
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
